Alamo Angels — 2022 Investments

1 investments dated 2022 · listed companies and verified rows first · show all

Arpeggio Bioarpeggiobio.com in 𝕏Series A · Sep 2022 · $17M

Arpeggio Bio develops pharmaceutical drugs that target transcription factors using artificial intelligence and RNA-sequencing technology, with lead programs in development for melanoma treatment and rare disease applications.

BiotechHealthtechBoulder, US

Joey Azofeifa(Founder)inLaura Norris(Executive Officer, Director)inTimothy Read(Executive Officer, Director)Eric Martin(Executive Officer)in

BoardAmit Mehta(Director)

Co-investorsFifty Years FundersClub Tau Ventures venBio Partners Y Combinator BoxOne Ventures +8 more

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.